Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: JCI Insight. 2016 May 19;1(7):e86873. doi: 10.1172/jci.insight.86873

Figure 5. Reduced expression of MCJ and the negative impact of low MCJ expression on survival is most evident in TNBC patients.

Figure 5

(A) MCJ expression was analyzed in breast cancers of the indicated subtypes using the Kaplan-Meier plotter database (integrating caBIG, GEO, and TCGA databases). A gradient of expression is shown across most classes, with statistical significance shown by letters at P < 0.01. Any comparison denoted with an “a” is not significantly different from another marked with an “a”. Similarly, “b” comparisons are not different from each other. However, “a”, “b”, and “c” are all different from each other. “ab” denotes a comparison not different from either “a” or “b” designation, but still denotes a difference from “c”. Further, a highly significant reduction in MCJ expression is seen in TNBC versus the other classes (P < 0.003). HER2+ER− (n = 162), ER+PR+ (n =74), luminal A (n = 908), luminal B (n = 436), ER+ (n = 844), TNBC (n = 384). (B and C) Kaplan-Meier curves were generated as in Figure 4, except that analyses were restricted to (B) triple-negative breast cancer (TNBC) patients known to have received chemotherapy (n = 53), and (C) HER2+ patients who received chemotherapy (n = 71).